The 5th ISCC

November 29-30, 2000
Keidanren Hall

Program November 29, 2000 (Wed)

09:30 - 9:35

Haruo Sugano (Cancer Chemotherapy Center, Tokyo, Japan)

Welcome and Introduction

I Genetic Approaches for Drug Discovery

Chairpersons: Paul Workman (Inst. Cancer Res., Sutton Surrey, U.K.)
Takashi Tsuruo (Univ. Tokyo, Tokyo, Japan)

09:35 - 10:05

Neil W. Gibson (Bayer Co., West Haven, USA)

Drug discovery in the new Millennium

10:05 - 10:25

Yusuke Nakamura (Univ. Tokyo, Tokyo, Japan)

p53-target genes

10:25 - 10:55

Paul Workman (Inst. Cancer Res., Sutton Surrey, UK)

Exploiting the molecular abnormalities responsible for cancer: Signal transduction drugs

10:55 - 11:05

Discussion

11:05 - 11:25

Coffee Break

11:25 - 11:45

Minoru Yoshida (Univ. Tokyo, Tokyo, Japan)

Histone deacetylase inhibitors--Discovery and coming generation

11:45 - 12:15

Peter J. Houghton (St. Jude Children’s Hosp., Memphis, USA)

Target of rapamycin (mTOR): a novel therapeutic target for cancer treatment

12:15 - 12:35

Tetsuya Kamataki (Hokkaido Univ., Sapporo, Japan)

Pharmacogenetics of CYP2A6: Lung cancer risk related to tobacco smoking, and metabolism of tegafur to 5-FU

12:35 - 12:50

Discussion

12:50 - 14:00

Lunch Break

II New Drugs under Clinical Consideration (Part I)

Chairpersons: Ross C. Donehower (Johns Hopkins Univ., Baltimore, USA)
Masahiro Fukuoka (Kinki Univ., Osaka, Japan)

14:00 - 14:30

Mace L. Rothenberg (Vanderbilt Univ., Nashville, USA)

Oxaloplatin: a novel platinum active in colorectal cancer

14:30 - 14:50

Holger Beckmann (Tularik Inc., South San Francisco, USA)

Novel approach for the treatment of multidrug-resistant cancers

14:50 - 15:10

Maurizio D’Incalci (Istituto di Ricerche Farmacologiche, Milano, Italy)

ET-743, a marine natural product with unique pharmacological properties and promising clinical activity

15:10 - 15:30

David Parkinson (Novartis Pharma. Co., East Hanover, USA)

STI571

15:30 - 15:40

Discussion

15:40 - 16:00

Coffee Break

III New Drugs under Clinical Consideration (Part II)

Chairpersons: Stanley B. Kaye (Univ. Glasgow, Glasgow, U.K.)
Yutaka Ariyoshi (Aichi Hospital, Nagoya, Japan)

16:00 - 16:20

Kazuhiko Nakagawa (Kinki Univ., Osaka, Japan)

ZD-1839

16:20 - 16:40

Noboru Horikoshi (Cancer Inst. Hosp., Tokyo, Japan)

TZT-1027

16:40 - 17:10

Eric Raymond (Institut Gustave-Roussy, Villejuif, France)

CCI-779, an ester analogue of rapamycin that interacts with PTEN/PI3 kinase pathways: a phase I and pharmacokinetic study utilizing a weekly intravenous schedule

17:10 - 17:40

Leonard Neckers (NCI, Bethesda, USA)

Preclinical and early clinical studies with 17-allylamino-17-demethoxy geldanamycin (17AAG)

17:40 - 18:00

Discussion

18:00 - 19:00

Mixer

November 30, 2000 (Thu)

IV New Immunological Approaches for Cancer Treatment

Chairpersons: Herbert M. Pinedo (Free Univ., Amsterdam, Netherlands)
Ryuzo Ueda (Nagoya City Univ., Nagoya, Japan)

09:30 - 09:50

Hiroshi Shiku (Mie Univ., Tsu, Japan)

Immunological cell therapy for cancer

09:50 - 10:20

Herbert M. Pinedo (Free Univ., Amsterdam, Netherlands)

The Spinoza trial: Longterm neo-adjuvant chemo-immunotherapy including GM-CSF

10:20 - 10:50

David G. Maloney (Fred Hutchinson Cancer Research Center, Seattle, USA)

Rituximab: Anti-CD20 antibody therapy of lymphoma

10:50 - 11:00

Discussion

11:00 - 11:20

Coffee Break

V New Strategy for Chemotherapy with Target-based Drugs

Chairpersons: Mace L. Rothenberg (Vanderbilt Univ., Nashville, USA)
Nagahiro Saijo (National Cancer Center Hosp., Tokyo, Japan)

11:20 - 11:50

Ross C. Donehower (Johns Hopkins Univ., Baltimore, USA)

New agents directed against tubulin and microtubles

11:50 - 12:20

Stanley B. Kaye (Univ. Glasgow, Glasgow, U.K.)

Novel approaches to overcome drug resistance

12:20 - 12:50

Michaele C. Christian (NCI, Bethesda, USA)

Assessing the effects of drugs on their putative targets

12:50 - 13:00

Discussion

13:00 - 13:10

Takashi Tsuruo (Univ. Tokyo, Tokyo, Japan)

Closing Remark

Page TOP